Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT02305186 |
| Title | Safety and Immunological Effect of Pembrolizumab in Resectable or Borderline Resectable Pancreatic Cancer |
| Acronym | UVA-PC-PD101 |
| Recruitment | Unknown status |
| Gender | both |
| Phase | Phase Ib/II |
| Variant Requirements | No |
| Sponsors | Osama Rahma, MD |
| Indications | |
| Therapies | |
| Age Groups: | adult |
| Covered Countries | USA |
| Facility | Status | City | State | Zip | Country | Details |
|---|---|---|---|---|---|---|
| Mayo Clinic Cancer Center | RECRUITING | Phoenix | Arizona | 85054 | United States | Details |
| Hartford HealthCare | RECRUITING | Hartford | Connecticut | 06102 | United States | Details |
| University of Miami | COMPLETED | Miami | Florida | 33136 | United States | Details |
| Dana-Farber Cancer Institute | RECRUITING | Boston | Massachusetts | 02215 | United States | Details |
| MD Anderson | RECRUITING | Houston | Texas | 77030 | United States | Details |
| University of Virginia Cancer Center | RECRUITING | Charlottesville | Virginia | 22908 | United States | Details |